The Interaction of Amyloid β and the Receptor for Advanced Glycation Endproducts Induces Matrix Metalloproteinase-2 Expression in Brain Endothelial Cells

Overview

Journal Cell Mol Neurobiol

Publisher Springer

Specialties Cell Biology
Molecular Biology
Neurology

Date 2011 Aug 13

PMID 21837459

Citations 23

Authors

Huan Du

Pengtao Li

Jun Wang

Xuemei Qing

Weihong Li

Affiliations

Soon will be listed here.

Abstract

The pathological hallmarks of Alzheimer's disease (AD) include formation of extracellular amyloid-β peptide (Aβ) and inflammatory responses. Numerous studies have reported that cerebral microvascular Aβ deposition promotes neuroinflammation in AD. Matrix metalloproteinases (MMPs) are involved in the cleavage of extracellular matrix proteins and regulation of growth factors, receptors, and adhesion molecules. Relatively little is known about the involvement of MMPs as inflammatory mediators in the pathological processes of AD. In this study, we explored the signaling pathway of MMP-2 up-regulation by Aβ in brain endothelial cells (BECs) of mice. Using Western blots, we found that inhibitors of extracellular-signal-regulated kinases (ERK) and c-Jun N-terminal kinase (JNK) significantly decreased Aβ-induced MMP-2 expression in BECs. Furthermore, antibody neutralization of the receptor for advanced glycation endproducts effectively blocked Aβ-induced activation of ERK and JNK and their contribution to elevated MMP-2 expression in BECs. Our results suggest that increased MMP-2 expression induced by the interaction of Aβ with RAGE in BECs may contribute to enhanced vascular inflammatory stress in Aβ-related vascular disorders, such as cerebral amyloid angiopathy and AD. This study offers new insights into neuroinflammation in the progression of AD.

Citing Articles

Cerebral Microbleeds Associate with Brain Endothelial Cell Activation-Dysfunction and Blood-Brain Barrier Dysfunction/Disruption with Increased Risk of Hemorrhagic and Ischemic Stroke.

Hayden M Biomedicines. 2024; 12(7).

PMID: 39062035 PMC: 11274519. DOI: 10.3390/biomedicines12071463.

rs243866 and rs2285053 Polymorphisms and Alzheimer's Disease Risk in Slovak Caucasian Population.

Ocenasova A, Shawkatova I, Javor J, Parnicka Z, Minarik G, Kralova M Life (Basel). 2023; 13(4).

PMID: 37109410 PMC: 10143987. DOI: 10.3390/life13040882.

The Role of Extracellular Matrix in Human Neurodegenerative Diseases.

Pinter P, Alpar A Int J Mol Sci. 2022; 23(19).

PMID: 36232390 PMC: 9569603. DOI: 10.3390/ijms231911085.

Dysfunction of the Blood-brain Barrier in Cerebral Microbleeds: from Bedside to Bench.

Wang H, Zhang C, Qiu Y, Chen A, Li Y, Hu B Aging Dis. 2021; 12(8):1898-1919.

PMID: 34881076 PMC: 8612614. DOI: 10.14336/AD.2021.0514.

Relationship Between Amyloid-β Deposition and Blood-Brain Barrier Dysfunction in Alzheimer's Disease.

Wang D, Chen F, Han Z, Yin Z, Ge X, Lei P Front Cell Neurosci. 2021; 15:695479.

PMID: 34349624 PMC: 8326917. DOI: 10.3389/fncel.2021.695479.

References

Basta G . Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis. 2007; 196(1):9-21. DOI: 10.1016/j.atherosclerosis.2007.07.025. View

Mlekusch R, Humpel C . Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels. Neurosci Lett. 2009; 466(3):135-8. PMC: 4311377. DOI: 10.1016/j.neulet.2009.09.043. View

McGeer P, Akiyama H, Itagaki S, McGeer E . Immune system response in Alzheimer's disease. Can J Neurol Sci. 1989; 16(4 Suppl):516-27. DOI: 10.1017/s0317167100029863. View

Tagliavini F, Ghiso J, Timmers W, Giaccone G, Bugiani O, Frangione B . Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab Invest. 1990; 62(6):761-7. View

Mizoguchi H, Takuma K, Fukuzaki E, Ibi D, Someya E, Akazawa K . Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice. J Pharmacol Exp Ther. 2009; 331(1):14-22. DOI: 10.1124/jpet.109.154724. View

Vinters H . Cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia?. Ann Neurol. 2001; 49(6):691-3. DOI: 10.1002/ana.1055. View

Lue L, Yan S, STERN D, Walker D . Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord. 2005; 4(3):249-66. DOI: 10.2174/1568007054038210. View

Yan S, Chen X, Fu J, Chen M, Zhu H, Roher A . RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996; 382(6593):685-91. DOI: 10.1038/382685a0. View

Li M, Shang D, Zhao W, Tian L, Li B, Fang W . Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol. 2009; 182(9):5778-88. DOI: 10.4049/jimmunol.0803013. View

10.

Du Yan S, Zhu H, Fu J, Yan S, Roher A, Tourtellotte W . Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A. 1997; 94(10):5296-301. PMC: 24672. DOI: 10.1073/pnas.94.10.5296. View

11.

Du H, Li P, Pan Y, Li W, Hou J, Chen H . Vascular endothelial growth factor signaling implicated in neuroprotective effects of placental growth factor in an in vitro ischemic model. Brain Res. 2010; 1357:1-8. DOI: 10.1016/j.brainres.2010.07.015. View

12.

Wang H, Ward N, Boswell M, Katz D . Secretion of brain-derived neurotrophic factor from brain microvascular endothelial cells. Eur J Neurosci. 2006; 23(6):1665-70. DOI: 10.1111/j.1460-9568.2006.04682.x. View

13.

Li W, Li P, Hua Q, Hou J, Wang J, Du H . The impact of paracrine signaling in brain microvascular endothelial cells on the survival of neurons. Brain Res. 2009; 1287:28-38. DOI: 10.1016/j.brainres.2009.06.057. View

14.

Tarkowski E . Cytokines in dementias. Curr Drug Targets Inflamm Allergy. 2003; 1(2):193-200. DOI: 10.2174/1568010023344670. View

15.

Girones X, Guimera A, Cruz-Sanchez C, Ortega A, Sasaki N, Makita Z . N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic Biol Med. 2004; 36(10):1241-7. DOI: 10.1016/j.freeradbiomed.2004.02.006. View

16.

Li W, Poteet E, Xie L, Liu R, Wen Y, Yang S . Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein. Brain Res. 2011; 1387:141-8. PMC: 3075344. DOI: 10.1016/j.brainres.2011.02.078. View

17.

Hofmann M, Drury S, Fu C, Qu W, Taguchi A, Lu Y . RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999; 97(7):889-901. DOI: 10.1016/s0092-8674(00)80801-6. View

18.

Koyama H, Yamamoto H, Nishizawa Y . RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med. 2007; 13(11-12):625-35. PMC: 2017106. DOI: 10.2119/2007-00087.Koyama. View

19.

Mun-Bryce S, Lukes A, Wallace J, Rosenberg G . Stromelysin-1 and gelatinase A are upregulated before TNF-alpha in LPS-stimulated neuroinflammation. Brain Res. 2002; 933(1):42-9. DOI: 10.1016/s0006-8993(02)02303-x. View

20.

Van den Steen P, Dubois B, Nelissen I, Rudd P, Dwek R, Opdenakker G . Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2003; 37(6):375-536. DOI: 10.1080/10409230290771546. View